The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose adjustment of axitinib based on AUC monitoring in sunitinib-refractory advanced renal cell carcinoma.
Yuji Miura
No relevant relationships to disclose
Chiyo K. Imamura
No relevant relationships to disclose
Keita Uchino
No relevant relationships to disclose
Takeshi Kishida
No relevant relationships to disclose
Nobuaki Matsubara
No relevant relationships to disclose
Toshiaki Shinojima
No relevant relationships to disclose
Mototsugu Oya
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Noboru Nakaigawa
Research Funding - Pfizer
Kenichi Yoshimura
No relevant relationships to disclose
Toshimi Takano
No relevant relationships to disclose
Yusuke Tanigawara
No relevant relationships to disclose